IPP Bureau
Lupin launches Rocuronium Bromide injection in US
By IPP Bureau - November 09, 2023
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
Bayer posts Q3 2023 Group sales Euro 10.34 billion
By IPP Bureau - November 09, 2023
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Biocon Biologics announces divestment of two non-core branded formulations
By IPP Bureau - November 09, 2023
Total transaction value of the divestment is Rs. 3,660 million
Evonik launches GMP-quality plant-based squalene
By IPP Bureau - November 08, 2023
PhytoSquene now available for clinical and commercial use
Indian pharmaceutical companies have become reliable and affordable suppliers of high-quality drugs: MoS Bhagwant Khuba
By IPP Bureau - November 08, 2023
Lack of technology transfer stands out as a formidable barrier
Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr
By IPP Bureau - November 08, 2023
Lupin receives USFDA tentative approval for Canagliflozin and Metformin Hydrochloride ER Tablets
By IPP Bureau - November 08, 2023
This product will be manufactured at Lupin’s Pithampur facility in India
Gland Pharma posts Q2 FY24 consolidated PAT at Rs. 194.08 Cr
By IPP Bureau - November 07, 2023
Gland Pharma has reported total income of Rs. 1426.57 crores during the period ended September 30, 2023
Sun Pharma Advanced Research posts Q2 FY24 loss at Rs. 86.42 Cr
By IPP Bureau - November 07, 2023
Sun Pharma Advanced Research Company Limited has reported total income of Rs. 29.67 crores during the period ended September 30, 2023
Max Healthcare Institute reports Q2 FY24 consolidated PAT at Rs. 276.68 Cr
By IPP Bureau - November 07, 2023
Max Healthcare Institute has reported total income of Rs. 1408.64 crores during the period ended September 30, 2023
Divis Laboratories posts Q2 FY24 consolidated PAT at Rs. 348 Cr
By IPP Bureau - November 07, 2023
Divi's Laboratories Limited has reported total income of Rs. 1995 crores during the period ended September 30, 2023
Zydus Wellness consolidated Q2 FY24 PAT drops to Rs. 5.9 Cr
By IPP Bureau - November 07, 2023
Zydus Wellness has reported total income of Rs. 444 crores during the period ended September 30, 2023
Metropolis Healthcare reports Q2 FY24 consolidated PAT at Rs. 35.45 Cr
By IPP Bureau - November 06, 2023
Metropolis Healthcare has reported total income of Rs. 309.71 crores during the period ended September 30, 2023
Orchid Pharma consolidated Q2 FY24 net profit up at Rs. 19.80 Cr
By IPP Bureau - November 06, 2023
Orchid Pharma reported total income of Rs. 207.11 crores during the period ended September 30, 2023
Themis Medicare posts Q2 FY24 PAT at Rs. 11.31 Cr
By IPP Bureau - November 06, 2023
The company has reported total income of Rs. 107.22 crores during the period ended September 30, 2023
